Methamphetamine self-administration acutely decreases monoaminergic transporter function

Synapse

Volumn 66, Issue 3, 2012, Pages 240-245

  McFadden, Lisa M ^a   Stout, Kristen A ^a   Vieira Brock, Paula L ^a   Allen, Scott C ^a   Nielsen, Shannon M ^a   Wilkins, Diana G ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Dopamine transporter; Methamphetamine; Vesicular monoamine transporter 2

Indexed keywords

AMPHETAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORE TEMPERATURE; CORPUS STRIATUM; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SYNAPSE VESICLE; SYNAPTOSOME;

AMPHETAMINE; ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84855276229     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21506     Document Type: Article

References (45)

1. Bowyer JF. 1995. The role of hyperthermia in amphetamine's interactions with NMDA receptors, nitric oxide, and age to produce neurotoxicity. Ann N Y Acad Sci 765: 309-310.
2. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Brennan KA, Colussi-Mas J, Carati C, Lea RA, Fitzmaurice PS, Schenk S. 2010. Methamphetamine self-administration and the effect of contingency on monoamine and metabolite tissue levels in the rat. Brain Res 1317: 137-146.
4. Brown JM, Hanson GR, Fleckenstein AE. 2000. Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74: 2221-2223.
5. Brown JM, Hanson GR, Fleckenstein AE. 2001. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther. 296(3) 762-7.
6. Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE. 2002. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther 302: 497-501.
7. Cervinski MA, Foster JD, Vaughan RA. 2005. Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J Biol Chem 280: 40442-40449.
8. Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, Fleckenstein AE. 2008. Differential regional effects of methamphetamine on dopamine transport. Eur J Pharmacol 590: 105-110.
9. Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE. 2010. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. J Neurochem 115: 325-332.
10. Clausing P, Bowyer JF. 1999. Time course of brain temperature and caudate/putamen microdialysate levels of amphetamine and dopamine in rats after multiple doses of D-amphetamine. Ann N Y Acad Sci. 890: 495-504.
11. Eyerman DJ, Yamamoto BK. 2007. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem 103: 1219-1227.
12. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR. 1997. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282: 834-838.
13. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. 2007. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
14. Fleckenstein AE, Volz TJ, Hanson GR. 2009. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56 (Suppl 1): 133-138.
15. Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang GJ, Wong C, Ma Y, Kriplani A, Pradhan K, Schlyer D, Jayne M, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog K. 2008. Fast uptake and long-lasting binding of methamphetamine in the human brain: Comparison with cocaine. Neuroimage 43: 756-763.
16. Frankel PS, Hoonakker AJ, Hanson GR. 2008. Differential response of neurotensin to methamphetamine self-administration. Ann N Y Acad Sci 1139: 112-117.
17. Frankel PS, Hoonakker AJ, Alburges ME, McDougall JW, McFadden LM, Fleckenstein AE, Hanson GR. 2011. Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. J Pharmacol Exp Ther 336: 809-815.
18. Hadlock GC, Baucum AJII, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. 2009. Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. J Pharmacol Exp Ther 329: 169-174.
19. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. 2011. 4-Methylmethcathinone(mephedrone): Neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
20. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG. 2004. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 309: 578-586.
21. Kish SJ. 2008. Pharmacologic mechanisms of crystal meth. CMAJ 178: 1679-1682.
22. Kokoshka JM, Vaughan RA, Hanson GR, Fleckenstein AE. 1998. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol 361: 269-275.
23. Kokoshka JM, Fleckenstein AE, Wilkins DG, Hanson GR. 2000. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine. J Neurochem 75: 2095-2102.
24. Krasnova IN, Cadet JL. 2009. Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379-407.
25. Krasnova IN, Justinova Z, Ladenheim B, Jayanthi S, McCoy MT, Barnes C, Warner JE, Goldberg SR, Cadet JL. 2010. Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat. PLoS One 5: e8790.
26. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35, 428. J Neurosci 18: 8417-8422.
27. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, Ye W, Alexander M, Dannals RF, Wong DF, Ricaurte GA. 2008. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62: 91-100.
28. McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE. 2011. Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration. Synapse 65: 771-777.
29. McFadden LM, Hadlock G, Allen SA, Vieira-Brock P, Stout KA, Ellis JD, Hoonakker A, Andrenyak DM, Nielsen SM, Hanson GR, Fleckenstein AE. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther (in press).
30. Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE. 2000. Methamphetamine-induced rapid decrease in dopamine transporter function: Role of dopamine and hyperthermia. J Pharmacol Exp Ther 295: 1077-1085.
31. Newton TF, Roache JD, De La Garza R II, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. 2006. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31: 1537-1544.
32. Pogun S, Baumann MH, Kuhar MJ. 1994. Nitric oxide inhibits [3H]dopamine uptake. Brain Res 641: 83-91.
33. Reichel CM, Schwendt M, McGinty JF, Olive MF, See RE. 2011. Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 36: 782-792.
34. Robertson SD, Matthies HJ, Galli A. 2009. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39: 73-80.
35. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. 2001. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: An in vitro model. J Neurosci 21: 1413-1419.
36. Schwendt M, Rocha A, See RE, Pacchioni AM, McGinty JF, Kalivas PW. 2009. Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J Pharmacol Exp Ther 331: 555-562.
37. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. 2001. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214.
38. Shepard JD, Chuang DT, Shaham Y, Morales M. 2006. Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology (Berl) 185: 505-513.
39. Stefanski R, Ladenheim B, Lee SH, Cadet JL, Goldberg SR. 1999. Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur J Pharmacol 371: 123-135.
40. Stefanski R, Lee SH, Yasar S, Cadet JL, Goldberg SR. 2002. Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration. Eur J Pharmacol 439: 59-68.
41. Sulzer D, Sonders MS, Poulsen NW, Galli A. 2005. Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 75: 406-433.
42. Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE. 2005. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity. J Pharmacol Exp Ther 314: 1087-1092.
43. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN. 2001. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
44. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703.
45. Yamamoto BK, Moszczynska A, Gudelsky GA. 2010. Amphetamine toxicities: Classical and emerging mechanisms. Ann N Y Acad Sci 1187: 101-121.